Navigation Links
HeartWare Presentation At The Canaccord Genuity Medical Technology & Diagnostics Forum To Be Webcast
Date:11/8/2013

FRAMINGHAM, Mass., Nov. 8, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Canaccord Genuity Medical Technology & Diagnostics Forum at 1:30 p.m. ET on Thursday, November 14, 2013.  The one-day conference is being held at the Westin Grand Central in New York City.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  A replay of the webcast will be available for 90 days at the site after the presentation.

About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, has received CE Marking in the European Union and has been used to treat patients in 36 international countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit the Company's website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare International Reports $54.8 Million In Third Quarter 2013 Revenue; 140% Increase From Third Quarter Of 2012
2. HeartWare Receives FDA Approval To Enroll Supplemental Patient Cohort In Destination Therapy Trial
3. HeartWare Presentation At The Canaccord Genuity 2013 Annual Growth Conference To Be Webcast
4. HeartWare Receives Conditional Approval From FDA to Enroll Supplemental Patient Cohort in Destination Therapy Trial
5. HeartWare Presentation at the Wells Fargo Securities 2013 Healthcare Conference to be Webcast
6. HeartWare International Announces Intention To Delist From Australian Securities Exchange (ASX)
7. HeartWare Presentation At The Goldman Sachs 34th Annual Global Healthcare Conference To Be Webcast
8. HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
9. HeartWare Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference to be Webcast
10. HeartWare International Reports $49.2 Million In First Quarter 2013 Revenue; 87% Increase From First Quarter Of 2012
11. HeartWare Schedules First Quarter Conference Call And Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed ...   ... Jim Bertolina, ... Tom Tefft ... medical device executive Josh Stopek , PhD, who has led R&D and business development ...
(Date:9/12/2017)... PARIS and NEW YORK , Sept. 12, ... ethical performance ratings for global supply chains, has published the first annual ... the CSR performance of more than 20,400 companies evaluated by EcoVadis, based ... years 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/9/2017)... INDIANAPOLIS , Sept. 9, 2017  Eli Lilly ... key primary and secondary endpoint data for lasmiditan, an ... migraine, which demonstrated statistically significant improvements compared to placebo ... be highlighted today at the 18th Congress of the ... . "The data presented today demonstrate lasmiditan,s ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... September 21, 2017 , ... 38-Year-Old Plastic Surgeon Gill at Aesthetic ... Florida is pleased to announce that Plastic Surgeon Kiranjeet Gill has been awarded as ... is an annual award that was started in 2003 to salute young achievers ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... learn with Infinity Behavioral Health Services for professionals in the addiction treatment industry ... Payer Audit . , Insurance companies and state and federal governments are ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... in their communities, nine governmental public health departments have been awarded five-year accreditation ... decisions mean that the benefits of being served by a PHAB-accredited health ...
(Date:9/21/2017)... ... 21, 2017 , ... Innovatum will demonstrate capabilities of fully ... Conference 2017 in Chicago, IL on October 17-19, 2017. This unique development addresses ... patient safety. , Microscan , a global technology leader in barcoding, ...
(Date:9/21/2017)... York, New York (PRWEB) , ... September 21, 2017 , ... ... exhibition, named “One Yoga Mat Revolution” on 6th, 7th and 8th October at Miranda ... couple’s renowned yoga mat art pieces, such as Zen Kodo mat. Wanderlust , ...
Breaking Medicine News(10 mins):